Last reviewed · How we verify
CT327 ointment
CT327 ointment is a topical treatment that targets the cannabinoid receptor type 2 (CB2) to reduce inflammation and pain.
CT327 ointment is a topical treatment that targets the cannabinoid receptor type 2 (CB2) to reduce inflammation and pain. Used for Treatment of pain associated with psoriasis.
At a glance
| Generic name | CT327 ointment |
|---|---|
| Sponsor | Creabilis SA |
| Drug class | CB2 receptor agonist |
| Target | CB2 |
| Modality | Small molecule |
| Therapeutic area | Pain management |
| Phase | Phase 2 |
Mechanism of action
CT327 ointment works by activating the CB2 receptor, which is involved in the regulation of inflammation and pain. This activation leads to a reduction in pro-inflammatory cytokines and an increase in anti-inflammatory cytokines, resulting in decreased pain and inflammation.
Approved indications
- Treatment of pain associated with psoriasis
Common side effects
- Skin irritation
Key clinical trials
- A Study to Evaluate the Efficacy, Safety and Tolerability of CT327 in Atopic Dermatitis (PHASE2)
- Evaluation of the Efficacy, Safety and Toleration of CT327 Ointment in Patients With Psoriasis Vulgaris (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |